20161005-ov-vancouver-vacv-antibody-poster-final-us
Category: Press release
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
20160905 – H1 update – EN – V10
Transgene Announces Participation at Upcoming Investor Events
20160901 – Next investor events – EN
Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
20160721 – Safety TG1050 EN Vdef
Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
20160531 – ASCO_Poster_PR_V2_clean
Composition of the Board of Directors and Statutory Auditors
20160525 – nomination Mr Beret – us
Transgene Reports First Quarter 2016 Business Update
20160421 PR VEN Q1 2016 – V4 clean
Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)
20160419 AACR Poster PR Final
Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team
20160317 Appointments PR Final
Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)
20160309 FY 2015 results version FINALE
